Group 1 - Over 180 A-shares and Hong Kong stocks have been included in the brokerage "golden stock" list for August, with Dongfang Zhihao being the most recommended stock by six brokerages [1][2] - The stocks with high attention include Dongpeng Beverage, Daikin Heavy Industries, Wanhua Chemical, Huadian Technology, and Luoyang Molybdenum [1][2] - The brokerage "golden stock" index for July showed that over 63% of the recommended stocks achieved positive returns, with Kangchen Pharmaceutical leading with a 106.74% increase [2][3] Group 2 - The market outlook for A-shares suggests a potential oscillating consolidation phase, benefiting growth stocks due to a weak dollar environment [1][4] - Analysts expect the A-share market to experience a gradual rise in index with increased volatility, influenced by policy expectations and economic recovery [4] - Key investment focuses include consumption sectors, technology (AI, robotics, semiconductors), dividend stocks, and gold [4] Group 3 - In the Hong Kong market, stocks like CNOOC, Pop Mart, and China Hongqiao are viewed positively by brokerages, with China Hongqiao reaching a historical high in stock price [2][4] - The overall performance of the Hong Kong market in July showed an upward trend, with expectations for continued growth in August due to stable domestic growth policies [4]

Group 1 - The core viewpoint of the news is that Guoyao Modern (600420) has experienced a decline in stock price and a significant net outflow of funds, despite a year-on-year increase in net profit for the first quarter of 2025 [1][3] - As of August 1, 2025, Guoyao Modern's stock closed at 11.39 yuan, down 0.7%, with a turnover rate of 1.79% and a trading volume of 240,300 hands, amounting to 276 million yuan [1] - The company's latest financial performance shows total operating revenue of 2.607 billion yuan for Q1 2025, a year-on-year decrease of 16.54%, while net profit attributable to shareholders was 361 million yuan, an increase of 9.10% [1] Group 2 - Guoyao Modern has a current liquidity ratio of 3.317, a quick ratio of 2.682, and a debt-to-asset ratio of 18.54%, indicating a strong liquidity position [1] - The company has made investments in 23 enterprises and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - Guoyao Modern holds 113 trademark registrations and 137 patents, along with 245 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]

证券代码：688166 证券简称：博瑞医药 公告编号：2025-053 博瑞生物医药（苏州）股份有限公司 关于与华润三九医药股份有限公司签署合作研发协 议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 博瑞生物医药（苏州）股份有限公司（以下简称"公司"或"博瑞医药" ） 及全资子公司博瑞制药（苏州）有限公司（以下简称"博瑞制药"） 、博瑞新创生 物医药科技（无锡）有限公司（该三家许可方统称为"博瑞医药及关联公司"） 与华润三九医药股份有限公司（以下简称"华润三九" ）签署了《合作研发协议》 ， 就 BGM0504 注射液在中国大陆地区（不包含香港、澳门及台湾地区）的研发、 注册、生产及商业化达成合作，博瑞医药及关联公司授予华润三九一项仅与博瑞 医药及关联公司合作的可分许可的排他性合作开发实施许可及一项可分许可的 独占性商业化实施许可。 ? 本协议的签署已履行了相应的内部审批程序，无需提交公司董事会及股 东大会审议。 ? 协议中约定的里程碑付款需要满足一定的条件，最终里程碑付款金额尚 存在不确定性 ...

Market Overview - The Hong Kong stock market continued to decline, with the Hang Seng Index falling by 1.07%, the National Enterprises Index down by 0.88%, marking four consecutive days of decline, and the Hang Seng Tech Index dropping by 1.02%, experiencing a seven-day downward trend [1][2] Stock Performance - Major technology stocks showed mixed results, with Baidu and Alibaba rising by 1% each, while Tencent fell nearly 3%, and Kuaishou dropped by 3.12% [2][3] - The Hang Seng Tech Index closed at 5397.40, down by 55.74 points or 1.02% [3] Sector Analysis - Financial and large-cap stocks faced renewed pressure, with many pharmaceutical stocks in the innovative drug sector experiencing significant declines [2][4] - The "anti-involution" concept saw a rebound, with paper and logistics stocks becoming active due to policy support [4][7] Trading Volume and Short Selling - The total trading volume for the Hang Seng Index was HKD 254.67 billion, indicating a noticeable decrease in volume compared to previous days [4] - The total short selling amount reached HKD 28.89 billion, accounting for 11.34% of the trading volume, with Tencent, Meituan, and Xiaomi leading in short selling amounts [5][4] Future Outlook - The market is currently testing support levels around 24,000 points, with potential for a rebound as short-selling pressures have eased [9] - Analysts suggest that the Hong Kong market remains within a reasonable valuation range compared to A-shares, with long-term recovery potential in technology and pharmaceutical sectors [11]

Group 1 - Yunnan Baiyao's stock closed at 56.29 yuan on August 1, 2025, with a slight increase of 0.37% and a turnover rate of 0.74% [1] - The company reported a total revenue of 10.841 billion yuan for Q1 2025, representing a year-on-year growth of 0.62%, while net profit attributable to shareholders was 1.935 billion yuan, up 13.67% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 2.895 and a quick ratio of 2.407, alongside a low debt-to-asset ratio of 24.81% [1] Group 2 - Yunnan Baiyao has made investments in 35 companies and participated in 5,000 bidding projects [2] - The company holds a significant number of intellectual property rights, including 2,242 trademark registrations and 501 patents [2] - Additionally, Yunnan Baiyao has obtained 1,202 administrative licenses [2]

Core Viewpoint - The financial performance of Haishike (002653) shows a mixed picture with revenue growth but a significant decline in net profit, indicating potential challenges ahead for the company [1]. Financial Performance - As of the first quarter of 2025, Haishike reported total revenue of 892 million yuan, representing a year-on-year increase of 18.60% [1]. - The net profit attributable to shareholders was 46.61 million yuan, a decrease of 49.31% year-on-year [1]. - The non-recurring net profit was 50.34 million yuan, showing a year-on-year growth of 69.25% [1]. - The company's liquidity ratios are strong, with a current ratio of 1.907 and a quick ratio of 1.695, while the debt-to-asset ratio stands at 40.59% [1]. Market Activity - On August 1, 2025, Haishike's stock closed at 53.87 yuan, down 3.44%, with a turnover rate of 0.99% and a trading volume of 53,000 lots, amounting to a transaction value of 289 million yuan [1]. - The net inflow of main funds was 13.16 million yuan, accounting for 4.55% of the transaction value, with large orders showing a net inflow of 24.19 million yuan [1]. Company Background - Haishike Pharmaceutical Group Co., Ltd. was established in 2005 and is primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 1.12 billion yuan and is located in Shannan City [1][2]. - Haishike has made investments in 20 enterprises and participated in 36 bidding projects, holding 493 trademark registrations and 69 patents [2].

Market Overview - On August 1, the A-share market saw a total of 51 stocks hit the daily limit up, with 40 stocks remaining after excluding 11 ST stocks, resulting in a limit-up rate of 62.96% [1] Hot Stocks - The stock with the highest limit-up order volume was Victory Energy, with 275,500 hands, followed by Yangzi New Materials, Wenkai Co., and Tianfu Cultural Tourism, with limit-up order volumes of 240,800 hands, 240,000 hands, and 189,900 hands respectively [2] - In terms of limit-up order funds, 17 stocks had order amounts exceeding 100 million yuan, with Beijiajie, Victory Energy, and Jiejia Weichuang leading at 430 million yuan, 385 million yuan, and 249 million yuan respectively [2] Industry Highlights Photovoltaic Sector - On August 1, multiple photovoltaic-related concepts saw collective gains, with the perovskite battery concept index rising by 2.42% and the photovoltaic inverter concept index increasing by 2.03% [3] - Key stocks in the photovoltaic sector included Jiejia Weichuang, which focuses on solar photovoltaic cell equipment and semiconductor equipment [4], and Shuangliang Energy, which specializes in polysilicon reduction furnaces, silicon wafers, and components [5] Pharmaceutical Sector - Notable stocks in the pharmaceutical sector included Qizheng Tibetan Medicine, which has pediatric products and is developing innovative traditional Chinese medicine [6], and Aoyikang, which focuses on innovative drugs and aims to build its own clinical and R&D team [6] Paper Industry - In the paper industry, Kain Co. provides high-end specialty food packaging paper for multinational chains like KFC and Starbucks, while Songyang Resources focuses on the research, production, and sales of environmentally friendly recycled paper [7] Investment Trends - The top net purchases on the Dragon and Tiger list included Jiejia Weichuang with over 100 million yuan, followed by other stocks like Longcheng Military Industry and Yidian Tianxia [8][9] - The net buying from the Shenzhen Stock Connect for Jiejia Weichuang was 172 million yuan, while the Shanghai Stock Connect saw net buying of Shuangliang Energy at 68.6 million yuan [9]

Group 1 - Luzhou Laojiao announced a cash dividend of 45.92 RMB per 10 shares for the 2024 fiscal year, totaling approximately 6.759 billion RMB [1] - The dividend will be distributed to all shareholders registered by the close of trading on August 7, 2025, with the ex-dividend date set for August 8, 2025 [1] Group 2 - Huatian Technology plans to establish a wholly-owned subsidiary, Nanjing Huatian Advanced Packaging Co., Ltd., with a total registered capital of 2 billion RMB to engage in 2.5D/3D integrated circuit packaging and testing [2] - The investment will be shared among its subsidiaries, with Huatian Jiangsu contributing 1 billion RMB (50%), Huatian Kunshan 665 million RMB (33.25%), and Advanced No. 1 335 million RMB (16.75%) [2] Group 3 - China Petroleum Engineering's subsidiary received a project award letter for a seawater pipeline project in Iraq, valued at approximately 18.032 billion RMB (2.524 billion USD) [3] - Successful signing and implementation of the project could enhance the company's market position in Iraq and the Middle East, positively impacting revenue and profit over the next 4-5 years [3] Group 4 - Jinghe Integrated is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries [4] - The H-share issuance will not change the company's controlling shareholder or actual controller [4] Group 5 - Huate Dain's subsidiary signed an exclusive distribution agreement for melatonin granules (Manlejing®) with Japan's Nobori Pharmaceutical, set to be approved for sale in mainland China by July 2025 [5] - This product will be the first melatonin formulation approved for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders in China [5] Group 6 - Baotai announced that its innovative drug BAT5906, a humanized monoclonal antibody injection, received clinical trial approval for new indications related to retinal conditions [6] - The drug has completed various phases of clinical trials for other indications and is preparing for further studies [6] Group 7 - Chipone Technology expects a revenue of approximately 584 million RMB for the second quarter, reflecting a quarter-on-quarter growth of 49.9% [7] - Qianli Technology reported July automobile sales of 10,200 units, a year-on-year increase of 142.34% [7] Group 8 - Hanma Technology's truck sales in July reached 956 units, marking a year-on-year growth of 42.69% [8] - Tianyi New Materials anticipates a net loss of 190 million to 240 million RMB for the first half of the year [8] Group 9 - Yabian Chemical signed a supply strategic agreement with Heng Rui Pharmaceutical [9] - Weisheng Information won procurement projects totaling 110 million RMB from South Grid and State Grid [9] - Dongjie Intelligent received a procurement order from PTT LOGISTICS SDN BHD worth approximately 62.5 million RMB [9]

Group 1 - The core viewpoint of the news is that Yipin Hong (300723) has experienced a decline in stock price and significant decreases in revenue and profit in its latest financial report [1] - As of August 1, 2025, Yipin Hong's stock closed at 75.72 yuan, down 2.37%, with a trading volume of 111,400 hands and a transaction amount of 868 million yuan [1] - The company's latest quarterly report shows total revenue of 377 million yuan, a year-on-year decrease of 39.48%, and a net profit attributable to shareholders of 56.59 million yuan, down 43.70% year-on-year [1] Group 2 - Yipin Hong has made investments in 12 companies and participated in 2 bidding projects, indicating active engagement in business expansion [2] - The company holds 308 trademark registrations and 16 patents, reflecting its focus on intellectual property [2] - Yipin Hong has 9 administrative licenses, which may enhance its operational capabilities [2]

金融界消息 截至2025年8月1日收盘，长春高新（000661）报收于105.69元，上涨0.16%，换手率 1.95%，成交量7.78万手，成交金额8.32亿元。 天眼查商业履历信息显示，长春高新技术产业(集团)股份有限公司，成立于1993年，位于长春市，是一 家以从事医药制造业为主的企业。企业注册资本40793.7529万人民币，实缴资本3803.8477万人民币。公 司法定代表人为姜云涛。 通过天眼查大数据分析，长春高新技术产业(集团)股份有限公司共对外投资了26家企业，参与招投标项 目13次，知识产权方面有商标信息30条，此外企业还拥有行政许可6个。 来源：金融界 资金流向方面，今日主力资金净流入1420.73万元，占比成交额1.71%。其中，超大单净流入2171.43万 元、占成交额2.61%，大单净流出750.70万元、占成交额0.9%，中单净流出流入1374.95万元、占成交额 1.65%，小单净流出2795.68万元、占成交额3.36%。 长春高新最新一期业绩显示，截至2025一季报，公司营业总收入29.97亿元、同比减少5.66%，归属净利 润4.73亿元，同比减少44.95%，扣非净利润4 ...